Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2014

Isis Earns $1M in Another Milestone Payment from GSK

  • Isis Pharmaceuticals received a $1 million milestone payment from GlaxoSmithKline (GSK) as part of an open-label extension study of ISIS-TTRRx. The product is being offered to patients with familial amyloid polyneuropathy (FAP) who have completed dosing in a Phase II/III study.

    ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

    This milestone payment is the third of the $50 million Isis is eligible to receive as the study progresses. Including this milestone payment, Isis has earned $25 million in upfront and milestone payments for advancing ISIS-TTRRx.

    In July 2013, the company won a $2 million milestone payment from GSK for the antisense drug. In the deal, Isis received $20 million in up-front and milestone payments before the dosing of the first patient in the study.

    If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis also is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx. The Phase II/III trial is a randomized, double-blind, placebo-controlled, international study designed to support an application for marketing approval of ISIS-TTRRx in patients with FAP. The fifteen month study will measure the effects of ISIS-TTRRx on neurological dysfunction and on quality-of-life.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »